louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01188915: Personalised Program for Women Treated for Hodgkin Disease
Official title: Personalised Program for Women Treated for Hodgkin Disease : Risk Evaluation of Breast Cancer and Intensive Screening Program for Women at High Risk of Breast Cancer. PROPER/IPC 2010-001
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Hodgkin Disease
Breast Cancer
Keywords: Hodgkin disease
Breast cancer
Lead sponsor: Institut Paoli-Calmettes
Sponsor class: OTHER
First posted: 2010-08-26
Enrollment: 51
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: After treatment for Hodgkin disease, secondary cancer, in particular breast cancer induced by treatment, are the first cause of death.

The investigators will estimate the risk to develop breast cancer in this population of women treated for hodgkin disease, and will propose women at high rish to participate in an intensive screening program based on an annual detection based on mammography, echography, and RMI.


Eligibility criteria: Inclusion Criteria:

* women \> 18 years
* treated for Hodgkin disease
* signed informed consent
* high risk of breast cancer

Exclusion Criteria:

* patients unable to have a regular follow-up

Primary outcomes:
measure: efficacy of the screening
timeFrame: 15 years
Secondary outcomes:
measure: interest
timeFrame: 1 month
measure: adhesion
timeFrame: 1 month
measure: compliance
timeFrame: 15 years
measure: psychologic impact
timeFrame: 15 years
Other outcomes:
Locations:
city: Marseille
country: France
facility: François EISINGER, PhD
Study officials:
affiliation: Institut Paoli-Calmettes
name: François EISINGER, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00532415: Safety and Efficacy of Vitreous Delineating Agent During Vitrectomy
Official title: Clinical Evaluation of the Safety and Efficacy of Triamcinolone Acetonide Suspension for Visualization During Vitrectomy Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Vitrectomy
Keywords: Vitrectomy
Visualization
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2007-09-20
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of triamcinolone acetonide suspension when used for visualization of structures in the back of the eye during eye surgery.


Eligibility criteria: Inclusion Criteria:

* Patients planning to undergo pars plana vitrectomy with good vision in the non-surgery eye.
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Patients under 18.
* Patients with previous vitrectomy, elevated intraocular pressure (IOP) and/or history of ocular inflammatory disease.
* Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Change in Mean Visualization Score at Post-Instillation from Pre-Instillation
timeFrame: Day 0
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00308815: Comparison of Manual Cardiopulmonary Resuscitation (CPR) Versus Automatic CPR Machine During Ambulance Transport.
Official title: Comparison of Manual Cardiopulmonary Resuscitation (CPR) Versus Automatic CPR Machine on the CPR Performance for Out-of-Hospital Cardiac Arrest During Ambulance Transport.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cardiac Arrest
Cardiopulmonary Resuscitation
Keywords: Resuscitation
Out-of-hospital cardiac arrest
cardiac arrest
CPR
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2006-03-30
Enrollment: 100
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a randomized controlled prospective study which assigned patient to receive manual CPR or automatic CPR machine use. The quality and efficacy between manual CPR and machine CPR will be evaluated.


Eligibility criteria: Inclusion Criteria:

* Non-traumatic out-of-hospital cardiac arrest patient in Taipei distric
* Patients sent to National Taiwan University Hospital (NTUH) through Jhongsiao Emergency medical service (EMS) team

Exclusion Criteria:

* Younger than 15 years old
* Traumatic cardia arrest
* Patients not sent to NTUH by Jhongsiao EMS team

Primary outcomes:
measure: Quality of CPR
Secondary outcomes:
measure: End-tidal CO2 on arrival at ER
measure: Recovery of spontaneous circulation (ROSC) rate
measure: Survival rate at 1hr, 24hr, and discharge from hospital
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Wen-Chu Chiang, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT02611115: Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.
Official title: Optimizing Tube Voltage Settings and Injection Parameters for the Individual Patient in CT Pulmonary Angiography.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Embolism
Keywords: Pulmonary Embolism
Multidetector Computed Tomography
Radiation Dosage
Contrast Media
Individualized Medicine
Lead sponsor: Maastricht University Medical Center
Sponsor class: OTHER
Collaborators: name: Bayer
First posted: 2015-11-20
Enrollment: 235
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Consecutive patients referred for CTPA with a clinical suspicion of pulmonary embolism will be included.

Brief summary: Computed tomographic pulmonary angiography (CTPA) is considered the gold standard for the diagnosis of pulmonary embolism (PE). PE is a potentially fatal disease in which a thrombus is lodged into a pulmonary artery blocking blood flow and potentially leading to respiratory distress, acute right cardiac failure or death. Therefore early and correct diagnosis is crucial.

The diagnostic and clinical value of CTPA has already been firmly substantiated. Unfortunately up to 7.3% of PE scans are still deemed to be non-diagnostic, for example due to insufficient contrast enhancement in the target arteries.

Therefore future research should focus on two important aspects of CT imaging. On the one hand optimal enhancement for the individual patient, on the other hand preventing additional risk of CT imaging - namely contrast induced nephropathy (CIN) and radiation risk. Thus the purpose of our study will be to optimize radiation dose settings (e.g. tube voltage, tube current) and CM application for the individual patient in CTPA.


Eligibility criteria: Inclusion Criteria:

* Suspicion of pulmonary embolism

Exclusion Criteria:

* Severe allergy against Iopromide or any of the ingredients, previous severe CM reaction (according to current ESUR guidelines), renal insufficiency, pregnancy

Primary outcomes:
measure: Image quality
timeFrame: one year
Secondary outcomes:
measure: Reduction of radiation dose
timeFrame: one year
Other outcomes:
Locations:
city: Maastricht
country: Netherlands
facility: Maastricht University Medical Center
state: Limburg
Study officials:
References:
Clinical trial NCT04353115: A Serious Game to Rehabilitate Gaze Stability in Children with Vestibular Deficit
Official title: Usability of a Serious Game to Rehabilitate Gaze Stability in Children with Vestibular Deficit: "Kids Gaze Rehabilitation"
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Vestibular Disorder
Keywords: Vestibular Disorder
serious game
vestibular rehabilitation
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2020-04-20
Enrollment: 12
Sex: ALL
Minimum age (years): 4
Maximum age (years): 13
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children with vestibular disorde

Brief summary: Since the early 2000s, vestibular rehabilitation has been proposed as a therapeutic tool to improve the balancing function and the various motor skills in children, in particular in children with hearing loss suffering from concomitant vestibular deficit. It has been demonstrated in adults with vestibular deficit that the fact of adding to the classic exercises on the control of balance per se and habituation, specific exercises of adaptation and substitution of the vestibulo-ocular reflex brought therapeutic benefit. These exercises, which are started in the presence of the physiotherapist and then continued by the patient himself at his home, aim to improve the stabilization of the gaze during head movements. In pediatrics, however, performing them is more difficult than conventional exercises, since their immediate interest is not well understood by the child, who may be reluctant to perform them. The present project aims to enrich the therapeutic offer by a pediatric rehabilitation method of eye stabilization sufficiently playful to win adherence to treatment, including in the absence of the physiotherapist when the child is at home.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with a vestibular disorder by the batteries of tests used in clinical routine.
* Supported by the multidisciplinary team of the Audiology and Otoneurological Exploration Department at the HFME
* Patient or parents able to understand the ins and outs of the study
* No opposition from children and parents

Exclusion Criteria:

* Associated visual sensorineural deficit
* Orthopedic or muscular disorder in the cervical spine

Primary outcomes:
measure: Numbers of patients able to use the serious game without side effects
timeFrame: Week 5
Secondary outcomes:
measure: side effects after the 5 weeks of intervention
timeFrame: Week 5
measure: Patient satisfaction
timeFrame: week 5
measure: Satisfaction of the patient's parents
timeFrame: Week 5
measure: Alouette test
timeFrame: Week 5
measure: Posturo-motor control
timeFrame: Week 5
measure: Visual acuity
timeFrame: Week 5
Other outcomes:
Locations:
city: Bron
country: France
facility: Pr THAI VAN
Study officials:
References:
Clinical trial NCT01755715: Immediate Versus Later Insertion of IUD After Medical Termination of Pregnancy
Official title: Immediate Versus Later Insertion of IUD After Medical Termination of Pregnancy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Contraception After Medical Abortion
Keywords: Abortion
Contraception
Intrauterine Devices
Intrauterine Device Expulsion
Lead sponsor: Helsinki University Central Hospital
Sponsor class: OTHER
First posted: 2012-12-24
Enrollment: 264
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main objective of this study is to compare, in a randomised, controlled and prospective fashion, initiation of intrauterine contraception (IUC) at about immediate (0 to 3 days) versus 2 to 4 weeks post medical abortion with regard to expulsions and use of contraception one year after abortion.


Eligibility criteria: Inclusion Criteria:

* Age ≥18 years
* Planning medical abortion
* Planning LNG-IUD (Mirena) contraception

Exclusion Criteria:

* Pathological pregnancies or abnormality of the uterus or cervix
* Acute endometritis

Primary outcomes:
measure: Number of expulsions
timeFrame: 1 year
measure: Use of IUD
timeFrame: 1 year
Secondary outcomes:
measure: Bleeding profile
timeFrame: 3 months
measure: Repeat abortions
timeFrame: 5 years
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: Helsinki University Central Hospital, Dept Ob&Gyn
Study officials:
affiliation: Helsinki University Central Hospital
name: Oskari Heikinheimo, MD, PhD
role: STUDY_DIRECTOR
affiliation: Helsinki University Central Hospital
name: Maarit Mentula, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06344637: Effects of Cervical Lidocaine Spray on Pain Relief During Manual Vacuum Aspiration
Official title: Effects of Cervical Lidocaine Spray on Pain Relief During Manual Vacuum Aspiration : A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Pain, Procedural
Lidocaine
Obstetric Surgical Procedures
Keywords: manual vacuum aspiration
pain score
Lidocaine spray
Lead sponsor: UdonThani Hospital
Sponsor class: OTHER_GOV
First posted: 2024-04-03
Enrollment: 216
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomized control trial aim to evaluate the effectiveness of local lidocaine spray application to the cervix on the reducing of pain score during the manual vacuum aspiration

Detailed description: This is a double blinded, placebo controlled study which compose of two arms. The treatment group is the local lidocaine spray application to the cervix with the intravenous opioid. The control group is the the intravenous opioid with the placebo (normal saline) before the manual vacuum aspiration. The outcome is to compare the visual analog pain score during and after procedure.

Eligibility criteria: Inclusion Criteria:

* female ageed 20 years to 60 years who have an indication for manual vacuum adpiration under intraveneous analgesia

Exclusion Criteria:

* patient with allergic to lidocaine or history of allergic to lidocaine
* patient with reproductive and urinary infection
* patient with abnormal vital sign
* patient with abnormal kidney and liver function test

Primary outcomes:
measure: pain score during manual vauum aspiration
timeFrame: during surgery
measure: pain score after manual vauum aspiration
timeFrame: at 30 minutes postoperative
Secondary outcomes:
Other outcomes:
Locations:
city: Udon Thani
country: Thailand
facility: UdonThani Hospital
state: UdonThani
Study officials:
affiliation: UdonThani Hospital
name: PATTARIKAN MANAYING
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02540915: The Pediatric Spine Foundation
Official title: The Pediatric Spine Foundation
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Chest Wall and Spinal Disorders
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
First posted: 2015-09-04
Enrollment: 5000
Sex: ALL
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients 17 and under that are being treated at Children's Hospital Colorado Orthopaedic department for a chest wall deformity, spine deformity and/or spinal disorder.

Brief summary: The Pediatric Spine Foundation is a registry designed to assist spine surgeons to efficiently identify and track patients with chest wall and spinal disorders.

Detailed description: The Pediatric Spine Foundation is a registry designed to assist spine surgeons to efficiently identify and track patients with chest wall and spinal disorders. The registry allows spine surgeons to participate in retrospective and prospective studies for specific spinal disorders.

Eligibility criteria: Inclusion Criteria:

* All patients 17 and under that are being treated at Children's Hospital Colorado Orthopaedic department for a chest wall deformity, spine deformity and/or spinal disorder. However, patients must be/have been 11 or under at their initial treatment/evaluation at Children's Hospital Colorado to be included in this study.

Exclusion Criteria:

* Enrollment in another spine registry

Primary outcomes:
measure: Clinical and radiographic measures for children with chest wall deformity, spine deformity and/or spinal disorder.
timeFrame: Approximately 10 years, recording each clinical and/or surgical visit the patient encounters at Children's Hospital Colorado.
Secondary outcomes:
Other outcomes:
Locations:
city: Aurora
country: United States
facility: Children's Hospital Colorado
state: Colorado
Study officials:
affiliation: Children's Hopsital Colorado
name: Sumeet Garg, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00368615: Characterization of the Melanoma-Specific Immune Response
Official title: Characterization of the Melanoma-Specific Immune Response
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Melanoma
Keywords: melanoma
malignant melanoma
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2006-08-25
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects aged 18 years to 85 years who have a biopsy diagnosis of melanoma, and age-matched controls (subjects who do not have a diagnosis of melanoma).

Brief summary: The aim of this study is to study T-cells. Blood will be collected and the samples will be used to generate T cell clones. Two separate blood draws will be required at the maximum.

Detailed description: The aim of the study is to in-vitro characterize and expand T cells specific for melanoma-derived antigens. Peripheral blood with be collected from 20 volunteers with biopsy proven melanoma and 10 age matched controls. Blood will be collected prior to the initiation of chemotherapy. There will be no more than two blood draws per patient. Most patients will receive a single blood draw; however, some participants may be asked to return for a single additional blood draw if investigators were unable to isolate melanoma-specific immune cells after the first blood draw. Two separate blood draws will be the maximum. The interval between these blood draws will be a minimum of 3 months apart. Blood samples will be used to determine the patient's HLA haplotype via PCR and DNA sequencing. After the patient's haplotype has been established melanoma-specific T cell clones will be generated from the peripheral blood samples and expanded in-vitro. These clones will then be assayed for specificity against commercially available melanoma cell lines. The T cell clones will also be assayed for reactivity to melanocyte differentiation antigens such as MART-1 and gp100. If the volunteer requires a palliative resection of a melanoma tumor then the patient's own tumor cells may also be used to test the specificity of the isolated T cell clones. All experiments will be conducted in-vitro.

Eligibility criteria: Inclusion Criteria:

* Biopsy diagnosis of malignant melanoma
* Have had a biopsy diagnosis of malignant melanoma in the past

Exclusion Criteria:

* Patients taking immunosuppressive medications

Primary outcomes:
measure: melanoma - peripheral blood
timeFrame: 2 Years
Secondary outcomes:
measure: melanoma - biopsy
timeFrame: 2 Years
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California, Davis Department of Dermatology
state: California
Study officials:
affiliation: University of California, Davis
name: Emanual Maverakis, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00291915: Multicenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis
Official title: Methotrexate Alone Versus Methotrexate in Combination With Adalimumab in Early Arthritis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Rheumatoid Arthritis
Arthritis
Keywords: early arthritis, methotrexate, adalimumab
Lead sponsor: Goupe d'Etudes et de Recherche Clinique En Rhumatologie
Sponsor class: OTHER
First posted: 2006-02-15
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluation of two treatment modalities in early potentially severe early arthritis ( Methotrexate alone or in combination with adalimumab)

Detailed description: Patients: early ( less than 6 months), active ( DAS\>5.2),potentially severe ( Leiden score\>6) Study design:12 months, prospective , randomized, open Study treatments: Methotrexate at a weekly dose of 0.3mg/kilo alone or in combination with adalimumab 40 mg every the other week Outcome measures: DAS over the 12 months

Eligibility criteria: Inclusion Criteria:

* Early Active Potentially severe arthritis

Exclusion Criteria:

* contra indication of methotrexate or anti TNF

Primary outcomes:
measure: Disease Activity Score
Secondary outcomes:
measure: -Radiological score
measure: -Functional impairment ( HAQ)
measure: -Pain (VAS)
Other outcomes:
Locations:
city: Paris
country: France
facility: Hopital Cochin
Study officials:
affiliation: Hopital Cochin Paris FRance
name: Maxime DOUGADOS, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00094315: Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1
Official title: Cocaine Relapse Prevention II
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Cocaine-Related Disorders
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
First posted: 2004-10-15
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes

Brief summary: To study of classical conditioning mechanisms associated with arousal, craving and cocaine use.

Detailed description: This is a single-site, double-blind, placebo-controlled crossover study of classical conditioning mechanisms associated with arousal, craving and cocaine use.

Eligibility criteria: Inclusion Criteria:

* Be English-speaking volunteers who are cocaine dependent
* Be non-treatment seeking at the time of the study
* Meet DSM-IV criteria for cocaine dependence
* Have ECG showing normal sinus rhythm, normal conductivity, and non clinically significant arrhythmias
* Females must provide a negative pregnancy test and agree to use birth control
* Have baseline laboratory tests within normal limits

Exclusion Criteria:

* Please contact site for more information

Primary outcomes:
measure: Stimulated and non-stimulated craving
measure: Cocaine assessment
Secondary outcomes:
Other outcomes:
Locations:
city: San Antonio
country: United States
facility: University of Texas Health Science Center
state: Texas
Study officials:
affiliation: University of Texas
name: John Roache, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: